Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
复制标题
DOI：
10.2176/nmc.ra2013-0200
复制
发表时间：
2013
影响因子：
1.9
通讯作者：
Date I
中科院分区：
文献类型：
--
作者：
Onishi M;Kurozumi K;Ichikawa T;Date I
尽管手术和药物治疗取得了进展，多形性胶质母细胞瘤（GBM）仍然是一种致命的疾病。在过去的20年里，患有这种疾病的患者的生存率没有显著增加。肿瘤血管的形成和胶质瘤细胞沿白质束的侵袭都在胶质瘤的发展中起关键作用。血管生成和血管生成被认为是导致肿瘤耐药的主要因素，更好地了解胶质瘤的侵袭和血管生成机制将有助于开发潜在的新治疗方法。本文就恶性胶质瘤血管生成和侵袭的分子特征作一综述。我们讨论了用于抑制GBM血管生成的贝伐单抗和西伦吉肽。
Despite advances in surgical and medical therapy, glioblastoma multiforme (GBM) remains a fatal disease. There has been no significant increase in survival for patients with this disease over the last 20 years. Tumor vasculature formation and glioma cell invasion along the white matter tracts both play a pivotal role in glioma development. Angiogenesis and invasion are the major factors believed to be responsible for treatment resistance in tumors, and a better understanding of the glioma invasion and angiogenesis mechanisms will lead to the development of potential new treatments. In this review, we focus on the molecular characteristics of angiogenesis and invasion in human malignant glioma. We discuss bevacizumab and cilengitide, which are used to inhibit angiogenesis in GBM.